Tags

Type your tag names separated by a space and hit enter

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.
Bone Marrow Transplant. 2017 May; 52(5):689-696.BM

Abstract

Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N=34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N=31, 91%) or a RIC (N=3, 9%) followed by post-transplant cyclophosphamide. After adjustment for significant covariates, MMUD and CB were associated with significantly lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR)=2.02, P=0.03 and HR=2.43, P=0.009, respectively) compared with HAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with post-transplant cyclophosphamide from HAPLO donors. Our findings suggest they should be favoured over MMUD and CB in this setting.

Authors+Show Affiliations

CHRU Lille, Pôle Spécialités Médicales et Gérontologie, Service des Maladies du Sang, Secteur Allogreffe de Cellules Souches Hématopoïétiques, Lille, France. UFR Médecine, Université de Lille, Lille, France.Department of Haematology, Humanitas Cancer Center, Rozzano, Italy.Agence Nationale de Biomédecine, Registre France Greffe de Moelle, Saint-Denis La Plaine, France.Department of Haematology, Nantes University Hospital, Nantes, France.Department of Haematology, Saint-Louis Hospital, APHP, Paris, France.Department of Haematology, Henri-Mondor Hospital, APHP, Paris, France.Department of Haematology, Poitiers University Hospital, Poitiers, France.Department of Haematology and Cellular Therapy, Haut-Lévêque University Hospital, Bordeaux, France.Department of Haematology, Rennes University Hospital, Rennes, France.Department of Haematology, Percy Hospital, Clamart, France.Department of Haematology, Caen University Hospital, Caen, France.Department of Haematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France.Department of Haematology, Angers University Hospital, Angers, France.Department of Haematology, Liège University Hospital, Liège, Belgium.Department of Haematology, Montpellier University Hospital, Montpellier, France.Department of Haematology, Limoges University Hospital, Limoges, France.Department of Haematology, Necker Hospital, APHP, Paris, France.Department of Haematology, Pitié Salpêtrière Hospital, APHP, Paris, France.Department of Haematology, Saint-Antoine Hospital, APHP, Paris, France.Department of Haematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.Department of Haematology, Toulouse University Hospital, Toulouse, France.Department of Haematology, Besançon University Hospital, Besançon, France.Department of Haematology, Loire Cancer Institute, Saint Priest en Jarez, France.Department of Haematology, Grenoble University Hospital, Grenoble, France.Department of Haematology, Lyon University Hospital, Lyon, France.Department of Haematology, Saint-Louis Hospital, APHP, Paris, France.CHRU Lille, Pôle Spécialités Médicales et Gérontologie, Service des Maladies du Sang, Secteur Allogreffe de Cellules Souches Hématopoïétiques, Lille, France. UFR Médecine, Université de Lille, Lille, France.Department of Haematology, Paoli Calmette Institute, Aix Marseille University, Centre de Recherche en Cancérologie, Inserm, CNRS UMR, Marseille, France.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

28067872

Citation

Gauthier, J, et al. "Reduced-intensity and Non-myeloablative Allogeneic Stem Cell Transplantation From Alternative HLA-mismatched Donors for Hodgkin Lymphoma: a Study By the French Society of Bone Marrow Transplantation and Cellular Therapy." Bone Marrow Transplantation, vol. 52, no. 5, 2017, pp. 689-696.
Gauthier J, Castagna L, Garnier F, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52(5):689-696.
Gauthier, J., Castagna, L., Garnier, F., Guillaume, T., Socié, G., Maury, S., Maillard, N., Tabrizi, R., Marchand, T., Malfuson, J., Gac, A., Gyan, E., Mercier, M., Béguin, Y., Delage, J., Turlure, P., Marçais, A., Nguyen, S., Dulery, R., ... Blaise, D. (2017). Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 52(5), 689-696. https://doi.org/10.1038/bmt.2016.349
Gauthier J, et al. Reduced-intensity and Non-myeloablative Allogeneic Stem Cell Transplantation From Alternative HLA-mismatched Donors for Hodgkin Lymphoma: a Study By the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52(5):689-696. PubMed PMID: 28067872.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. AU - Gauthier,J, AU - Castagna,L, AU - Garnier,F, AU - Guillaume,T, AU - Socié,G, AU - Maury,S, AU - Maillard,N, AU - Tabrizi,R, AU - Marchand,T, AU - Malfuson,J, AU - Gac,A, AU - Gyan,E, AU - Mercier,M, AU - Béguin,Y, AU - Delage,J, AU - Turlure,P, AU - Marçais,A, AU - Nguyen,S, AU - Dulery,R, AU - Bay,J, AU - Huynh,A, AU - Daguindau,E, AU - Cornillon,J, AU - Régny,C, AU - Michallet,M, AU - Peffault de Latour,R, AU - Yakoub-Agha,I, AU - Blaise,D, Y1 - 2017/01/09/ PY - 2016/10/02/received PY - 2016/11/12/revised PY - 2016/11/21/accepted PY - 2017/1/10/pubmed PY - 2018/3/6/medline PY - 2017/1/10/entrez SP - 689 EP - 696 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 52 IS - 5 N2 - Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N=34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N=31, 91%) or a RIC (N=3, 9%) followed by post-transplant cyclophosphamide. After adjustment for significant covariates, MMUD and CB were associated with significantly lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR)=2.02, P=0.03 and HR=2.43, P=0.009, respectively) compared with HAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with post-transplant cyclophosphamide from HAPLO donors. Our findings suggest they should be favoured over MMUD and CB in this setting. SN - 1476-5365 UR - https://www.unboundmedicine.com/medline/citation/28067872/Reduced_intensity_and_non_myeloablative_allogeneic_stem_cell_transplantation_from_alternative_HLA_mismatched_donors_for_Hodgkin_lymphoma:_a_study_by_the_French_Society_of_Bone_Marrow_Transplantation_and_Cellular_Therapy_ L2 - https://doi.org/10.1038/bmt.2016.349 DB - PRIME DP - Unbound Medicine ER -